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Abstract
Objective:  To  identify  and  quantify  the  adverse  effects  associated  with  the  recombinant  human
papillomavirus  (types  6,  11,  16  and  18)  vaccine  in  adolescents.
Data source:  Systematic  review  of  randomized  clinical  trials  from  PubMed,  SciELO  and  Lilacs
databases.  Articles  investigating  the  safety  of  the  vaccine  in  subjects  under  18  years  and  com-
paring the  recombinant  human  papillomavirus  types  6,  11,  16  and  18  vaccine  with  a  control  group
were included.  Meta-analyses  were  performed  for  the  outcomes  of  pain,  erythema,  swelling  and
fever, using  clinical  trials  with  maximum  Jadad  score.
Data  synthesis:  Fourteen  studies  were  included.  The  most  common  adverse  effects  related  to
the human  papillomavirus  vaccine  were  effects  with  no  severity  (pain,  erythema,  edema,  and
fever). Five  studies  were  used  for  the  meta-analyses:  pain--risk  difference  (RD)=11%  (p<0.001);
edema--RD=8%  (p<0.001);  erythema--RD=5%  (p<0.001);  fever--RD=2%  (p<0.003).
Conclusions:  The  recombinant  human  papillomavirus  types  6,  11,  16  and  18  vaccine  was  safe
and well  tolerated.  The  main  adverse  effects  related  to  vaccination  were  pain,  erythema,
edema and  fever.  The  low  frequency  of  severe  adverse  effects  encourages  the  administration
of the  vaccine  in  the  population  at  risk.
© 2015  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-  license  (https://creativecommons.org/licenses/by/4.0/).DOI of original article: http://dx.doi.org/10.1016/j.rpped.2015.02.006
∗ Corresponding author.
E-mail: plsc.fcms@gmail.com (P.L.S. Coelho).
359-3482/© 2015 Sociedade de Pediatria de Sa˜o Paulo. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-
icense (https://creativecommons.org/licenses/by/4.0/).
Safety  of  human  papillomavirus  6,  11,  16  and  18  (recombinant)  475
PALAVRAS-CHAVE
Vacinas  contra
papillomavirus;
Efeitos  adversos;
Adolescente;
Metanálise;
Seguranc¸a
Seguranc¸a  da  vacina  papillomavirus  humano  6,  11,  16  e  18  (recombinante):  revisão
sistemática  e  metanálise
Resumo
Objetivo:  Identiﬁcar  e  quantiﬁcar  os  efeitos  adversos  associados  à  vacina  papillomavirus
humano  6,  11,  16  e  18  (recombinante)  em  adolescentes.
Fontes de  dados:  Revisão  sistemática  de  ensaios  clínicos  randomizados  nas  bases  de  dados  do
PubMed,  SciELO  e  Lilacs.  Foram  incluídos  artigos  que  abordavam  a  seguranc¸a da  vacina  em
menores de  18  anos  e  que  comparavam  a  vacina  papillomavirus  humano  6,  11,  16  e  18  (recom-
binante)  com  grupo  controle.  Foram  feitas  metanálises  para  os  desfechos  de  dor,  eritema,
edema e  febre  com  o  uso  de  ensaios  clínicos  com  escore  de  Jadad  máximo.
Síntese  dos  dados: Foram  incluídos  14  estudos.  Os  efeitos  adversos  mais  comuns  relacionados
à vacina  foram  intercorrências  sem  gravidade  (dor,  eritema,  edema  e  febre).  Cinco  estudos
foram usados  para  as  metanálises,  incluindo  os  desfechos:  Dor  --  Diferenc¸a  de  Risco  (DR)=11%
(p<0,001);  Edema  --  DR=8%  (p<0,001);  Eritema  --  DR=5%  (p<0,001);  Febre  --  DR=2%  (p<0,003).
Conclusões:  A  vacina  papillomavirus  humano  6,  11,  16  e  18  (recombinante)  mostrou-se  segura
e bem  tolerada.  Os  principais  efeitos  adversos  relacionados  à  vacinac¸ão  foram  dor,  eritema,
edema e  febre.  A  baixa  frequência  de  efeitos  adversos  graves  encoraja  a  aplicac¸ão  da  vacina
na populac¸ão  de  risco.
©  2015  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este  é  um  artigo
Open Access  sob  a  licença  CC  BY  (https://creativecommons.org/licenses/by/4.0/deed.pt).
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Cervical  cancer  is  the  second  most  common  type  of  cancer
that  affects  women  worldwide,  with  an  incidence  of  approx-
imately  500,000  cases  and  270,000  deaths  each  year.1,2 The
disease  is  often  detected  at  advanced  stages  due  to  the
lower  efﬁciency  of  screening  strategies  in  the  initial  stage
and  treatment  options  that  are  not  always  effective.3--6 At
least  80%  of  deaths  from  cervical  cancer  occur  in  develop-
ing  countries,  most  of  them  in  the  poorest  regions  of  the
world,  such  as  Southern  Asia,  Sub-Saharan  Africa  and  parts
of  Latin  America.  In  those  areas,  which  receive  only  5%  of
the  resources  for  cancer  in  the  world,  cervical  involvement
is  responsible  for  15%  of  all  cancer  deaths.7
Infection  by  human  papillomavirus  (HPV)  is  a  common
occurrence,  and  the  probability  of  acquiring  it  throughout
an  individual’s  lifetime  is  higher  than  50%.8 Approximately
35--40  types  of  HPV  can  infect  the  genital  epithelium.  The
infection  may  be  transient  and  not  clinically  detectable,  but
can  also  cause  genital  warts  and  a  variety  of  pre-malignant
and  malignant  anogenital  lesions  in  both  genders.9--14 Stud-
ies  show  that  the  peak  incidence  of  HPV  infection  occurs
5--10  years  after  the  ﬁrst  sexual  intercourse  (between  15
and  25  years  old),15--19 and  infection  persistence  by  an  onco-
genic  HPV  type  is  crucial  in  the  pathogenesis  of  cervical
cancer.2,20--22 Thus,  it  becomes  possible  to  prevent  the  dis-
ease  onset  through  vaccination  before  the  start  of  sexual
activity.19,23--26
The  currently  available  vaccines  against  HPV  differ  in  the
number  of  genotypes,  in  the  way  they  are  manufactured  and
the  adjuvant  they  contain.  Both  vaccines  currently  available
for  use,  bivalent  and  quadrivalent,  are  highly  immunogenic
and  prevent  the  primary  infection  against  HPV  genotypes
and  CIN  2/3  adenocarcinoma  (CIN  --  cervical  intraepithe-
lial  neoplasia,  which  refers  to  squamous  epithelial  lesions
a
p
t
mn  the  lower  genital  tract,  which  are  precursors  of  invasive
ancer,  presenting  as  tissue  impairment,  from  cytoplasmic
lterations  to  severe  dysplasia).  Studies  indicate  a  very  sim-
lar  safety  proﬁle  for  severe  and  mild  adverse  effects  for
ach  one  of  the  vaccines.27,28
The  introduction  of  new  vaccines  requires  safety  stud-
es.  Concerns  about  the  adverse  effects  is  considered  a
arrier  to  vaccination  and  one  of  the  reasons  for  low
dherence  to  the  recommendations  for  human  papillo-
avirus  quadrivalent  (types  6,  11,  16,  18)  recombinant
accine  administration.29,30 The  opinion  of  health  profes-
ionals  regarding  its  safety  is  yet  to  be  unanimous.  Several
ebates  have  been  carried  out  with  persistent  controver-
ies  about  the  advantages  and  disadvantages  of  its  use.
herefore,  the  knowledge  of  the  possible  local  and  sys-
emic  adverse  effects  can  subsidize  adherence  strategies
nd  guide  health  care  actions  for  the  population  at  risk.
Therefore,  the  objective  of  this  study  is  to  identify  and
uantify  the  adverse  effects  associated  with  the  adminis-
ration  of  the  human  papillomavirus  quadrivalent  (types  6,
1,  16,  18)  recombinant  vaccine,  as  a  tool  to  determine  the
afety  of  its  use  in  adolescents.
ethod
 search  for  publications  was  carried  out  in  April  2014,
n  the  National  Center  for  Biotechnology  Information
dvances  Science  and  Health  --  US  National  Library  of
edicine  --  National  Institutes  of  Health  --  PubMed  elec-
ronic  databases,  with  no  restrictions  regarding  date
nd  language  of  publication.  Additionally,  a  search  was
erformed  in  the  LILACS  and  SciELO  databases  using
he  descriptor  ‘‘Papillomavirus  Vaccines’’,  followed  by  a
anual  search  for  randomized  controlled  trials  (RCTs).  In
4 Coelho  PLS  et  al.
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Table  1  Frequency  of  identiﬁcation  (FI)  and  prevalence
interval  (PI)  of  adverse  effects  associated  with  the  HPV  vac-
cine and  identiﬁed  in  14  selected  randomized  controlled
trials.
Adverse  effects  FI  PI  (%)
Local
Local  pain  13  20.2--88.4
Edema 12  3.0--31.0
Erythema  11  1.0--41.0
Pruritus  3  1.1--4.1
Systemic
Fever 12  2.7--23.5
Fatigue  9  0.3--38.8
Headache  12  5.3--35.2
Cough 2  3.6
Arthralgia  7  5.5--13.4
Myalgia 8  3.6--33.9
Sore throat 3  0.4--4.0
Nausea 2  0.8--2.6
Chills 1  --
Abdominal  pain 2  0.3
Diarrhea  and/or  vomiting 12  0.5--19.3
Acne 1  0.8
Dizziness  and  vertigo 3  1.0
Diseases
Psychiatric  2  1.7--2.2
Blood and  lymphatic  system  1  0.4
Cardiovascular  3  0.1--0.6
Ear and  labyrinth  1  1.2
Nervous  system  4  1.3--33.7
Ocular 1  1.0
Immunological/allergies  3  0.6--2.6
Metabolic  and  nutritional  1  0.8
Infectious  1  20.7
Renal and  urinary  3  0.4--1.4
Reproductive  and  breasts  1  8.4
Respiratory,  thoracic  or  mediastinal  1  0.9--7.7
Skin and  subcutaneous  tissue  3  4.2
Musculoskeletal  and  of  connective  tissue  5  1.1--9.1
Mastoiditis  1  --
Upper airways  infections  11  0.1--6.0
Diabetes  mellitus  2  --
Renal failure  1  --
Poisoning,  trauma  2  --
Intoxication  1  1.7
Appendicitis  1  --
Rash/hives  7  0.8--6.6
Hypothyroidism  1  0.4
Malaria 1  --
Perinatal
Dysfunctional  uterine  bleeding  1  --
Prematurity  2  --
Congenital  anomaly  1  2.3
Late fetal  death  1  --76  
he  ﬁrst  stage  of  article  selection, the  Decs/Mesh  health
escriptor  ‘‘papillomavirus  vaccines/adverse  effects’’  was
sed.  The  study  design  ﬁlter  ‘‘RCTs’’  was  added  to  the
btained  results.  Subsequently,  the  identiﬁed  articles  were
nalyzed  by  reading  the  titles  and  abstracts.
At  this  stage,  the  exclusion  criteria  of  the  articles  were:
oncurrent  use  of  HPV  vaccine  with  other  vaccines;  use  of
he  vaccine  in  patients  who  already  had  cervical  diseases;
atients  positive  for  HIV;  patients  who  had  already  received
he  HPV  vaccine;  studies  on  the  acceptance  among  family
embers  of  the  administration  of  HPV  vaccine  in  adoles-
ents;  studies  carried  out  exclusively  with  patients  aged  >18
ears;  repeated  studies  and  systematic  reviews.
All  other  studies  were  read  in  full,  analyzed  by  ﬁve  inde-
endent  investigators  and  classiﬁed  according  to  the  Jadad
core.31 In  this  classiﬁcation,  one  point  was  attributed  for
ach  of  the  following  items:  description  of  article  as  ran-
omized  trial  and  description  of  article  as  double  blind;  one
dditional  point  for  each  of  the  articles  of  which  method
as  described,  and  in  case  it  was  appropriate;  the  point  for
andomization  and  blinding  was  subtracted  if  the  method
sed  for  those  was  inappropriate;  and  an  additional  point
or  description  of  losses.
After  this  step,  the  researchers  met  at  a  panel  discussion
n  eligibility  criteria.  Therefore,  articles  that  evaluated  the
afety  of  HPV  bivalent  and  quadrivalent  vaccines,  in  both
enders,  with  Jadad  score31 ≥3  were  included.  The  process
f  article  selection  is  shown  in  Fig.  1.
Initially,  all  adverse  effects  identiﬁed  in  the  selected
CTs  were  listed.  The  selected  articles  were  described
ccording  to  the  results  shown  in  each  of  the  RCTs,  dis-
losing  prevalence  data  and  characteristics  of  the  identiﬁed
dverse  effects.  Subsequently,  four  meta-analyses  of  four
ifferent  outcomes  evaluated  in  RCTs  (pain,  edema,  ery-
hema,  fever)  were  performed,  which  included  articles  with
adad  score  =  531 and  compared  their  occurrence  between
he  group  that  received  the  HPV  quadrivalent  vaccine  and
he  placebo  group.
The  statistical  package  Review  Manager  5.2  software  was
sed.  The  results  were  expressed  as  risk  difference  (RD)  with
xed  conﬁdence  interval  of  95%  and  a  statistical  signiﬁcance
evel  with  a  maximum  p=0.05  (5%).  Heterogeneity  was  calcu-
ated  using  the  statistical  Mantel--Haenszel  chi-square  test,
nd  expressed  as  I2,  and  those  with  value  >50%  (I2>50%)  were
onsidered  heterogeneous.  Asymmetries  were  represented
n  the  funnel  plot.
esults
 total  of  14  RCTs  were  included  in  this  study,  none  of
hem  from  the  SciELO  or  LILACS  databases.  Table  1  shows
he  adverse  effects  associated  with  the  administration  of
he  human  papillomavirus  quadrivalent  (types  6,  11,  16,
8)  recombinant  vaccine,  without  necessarily  establishing  a
ausal  link  between  the  vaccine  and  the  effects,  indicating
ow  many  of  these  studies  identiﬁed  them  and  the  variations
etween  prevalence  rates.
Table  2  describes  the  characteristics  of  the  selected  stud-
es  during  the  search  process,23,32--43 including  authorship,
ear  of  publication,  classiﬁcation  according  to  the  Jadad
Miscarriage  1  22.2
FI, frequency of identiﬁcation; PI, prevalence interval.
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Results obtained from Pubmed
database (n=372)
RCT filter applied (n=37)
Excluded (n=21): 
HPV concurrently with other
vaccines (n=5) 
Installed cervical disease (n=1)
HIV-positive patients (n=1)
Prior HPV vaccination (n=1) 
Vaccine acceptance (n=2) 
Age >18 years (n=7) 
Duplicated articles (n=1) 
Review articles (n=3)
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Results after removal of articles that did
not answer the question (n=16)
Full-text articles assessed (n=16)
El
ig
ib
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y Excluded (n=2) :
Jadad score <3 (n=2)
Studies included in the qualitative analysis (n=14)
In
cl
us
io
n
Studies
included in the
meta-analysis
(pain) (n=5)
Studies
included in the
meta-analysis
(fever) (n=4)
Studies
included in the
meta-analysis
(erythema) (n=3)
Studies
included in the
meta-analysis
(edema) (n=3)
Excluded (n=502)
Results obtained from additional
databases:
SciELO (n=57) & LILACS (n=110)
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tFigure  1  Artic
score,31 methodology  used  and  the  adverse  effects  that  were
statistically  related  to  the  vaccine.
Among  the  analyzed  studies,  there  was  only  one  case
of  severe  adverse  event  related  to  the  vaccine,  which  was
bronchospasm.32 The  others  showed  no  reports  of  vaccine-
related  severe  adverse  effects  or  deaths.  The  incidence  of
adverse  effects  was  higher  after  the  ﬁrst  dose  of  the  vaccine
schedule,  with  a  reduction  in  their  occurrence  at  subsequent
doses.23,33--36,43
The  selection  of  outcomes  for  the  meta-analyses  was
carried  out  according  to  the  frequency  of  appearance
of  adverse  effects  assessed  in  the  selected  publications,
comparing  their  occurrence  between  vaccinated  and  unvac-
cinated  subjects  against  HPV,  emphasizing  the  local  effects
(pain,  erythema  and  edema)  and,  as  systemic  effect,  fever.
This  analysis  was  performed  with  ﬁve  studies  with  a  Jadad
score31 of  5,32--34,36,43 without  gender  or  age  group  restric-
tion  for  the  quadrivalent  vaccine,  with  four  of  them  being
1
v
r
clection  process.
ulticenter  studies32--34,36 and  one  having  been  carried  out
n  South  Korea.43 The  meta-analysis  results  for  the  ‘‘pain’’,
‘edema’’,  ‘‘erythema’’  and  ‘‘fever’’  outcomes  are  shown
n  Fig.  2.
For  the  ‘‘pain’’  outcome,  the  meta-analysis  assessed
ve  RCTs,  totaling  12,060  participants,  6348  vaccinated
or  HPV  and  5712  placebo-controlled.  Of  the  vaccinated
nes,  4704  had  pain  at  the  injection  site,  while  only  3639
eported  the  same  outcome  with  the  placebo,  resulting  in
n  RD=11%  (95%CI:  9--13%;  I2=93%),  therefore  being  signiﬁ-
antly  more  common  after  the  administration  of  the  vaccine
p<0.001).
The  ‘‘edema’’  outcome  was  analyzed  in  three  multicen-
er  articles.32,34,36 These  included  5783  patients,  of  which
154  developed  edema  at  the  injection  site  in  the  group
accinated  for  HPV,  and  645  of  5206  in  the  placebo  group,
esulting  in  an  RD=8%  (95%CI:  6%--9%;  I2=96%)  for  this  out-
ome  in  favor  of  the  vaccinated  group  (p<0.001).
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Table  2  Characteristics  of  14  randomized  clinical  trials  selected  by  the  used  search  criteria.
Author  (year/JADAD)  Method  Effects  associated  with  the
vaccineDesign  Intervention  Gender  (age
range)
Moreira  et  al.  [34]
(2011/5)
RCT,  DB,  PC  HPV  QV  (n=1945)  vs.
Placebo  (n=1950)
M  (16--26  yrs)  Local  pain
Kim et  al.  [23]
(2010/5)
RCT  HPV  DV  (n=474)  vs.  hepatitis
A  vaccine  (n=483)
F  (10--14  yrs)  Local  pain,  erythema,
edema  and  myalgia
Sow et  al.  [35]
(2013/5)
RCT  IIIb,  DB,
PC,  MULTI
(aluminum
hydroxide)
HPV  DV  (n=1298)  vs.
Placebo  (n=643)
F  (10--25  yrs)  Local  pain
Reisinger et  al.  [36]
(2007/5)
RCT,  DB,  PC HPV  QV  (n=1165)  vs.
Placebo  (n=584)
M  and  F  (1:1)
(9--15  yrs)
Local  pain,  erythema  and
edema
Szarewski et  al.  [37]
(2012/5)
RCT,  DB  HPV  DV  (n=9319)  vs.
hepatitis  A  vaccine  (n=9325)
F  exposed  to  HPV
(15--25  yrs)
Local  pain,  erythema  and
edema
Petäjä et  al.  [38]
(2009/3)
RCT,  phase
I/II,  blind
observer
HPV  DV  (n=181)  vs.  hepatitis
B  vaccine  (n=89)
M  (10--18  yrs)  Local  pain,  edema  and
myalgia
FUTURE II  [33]
(2007/5)
RCT,  DB,  PC  HPV  QV  (n=448)  vs.  Placebo
(n=447)
F  (15--26  yrs)  Local  pain,  seasonal
allergies
Medina et  al.  [39]
(2010/3)
RCT,  MULTI  HPV  DV  (n=1017)  vs.
hepatitis  A  vaccine  (n=1010)
F  (10--14  yrs)  Local  pain,  erythema,
edema,  headache,  myalgia,
fatigue,  hives  and  syncope
Romanowski et  al.  [40]
(2011/3)
RCT  phase
I/II,  PB;  2
vs.  3  doses
of  divalent
HPV
2 Doses  FOR20/20  M0/6
(n=240);  2  doses  FOR40/40
M0/6  (n=241);  2  doses
FOR40/40  M0/2  (n=240);  3
doses  FOR20/20  0/1/6
(n=239)
F  (9--25  yrs)  --
Garland et  al.  [32]
(2007/5)
RCT,  DB,  PC,
MULTI
HPV  QV  (n=2673)  vs.
Placebo  (n=2672)
F  (16--24  yrs)  Local  pain,  erythema,
edema  and  local  pruritus,
fever  >38.9 ◦C,
bronchospasm
Petäjä et  al.  [41]
(2011/3)
RCT  phase
III,  MULTI
HPV  DV  (n=616)  F  (10--25  yrs)  --
Esposito et  al.  [42]
(2011/3)
RCT,
standard
schedule
(0/1/6  m)
vs.
alternative
(0/1/12  m)
HPV  DV  standard  (n=1195)
vs.  HPV  DV  alternative
(n=1188)
F  (15--25  yrs)  --
Kang et  al.  [43]
(2008/5)
RCT,  DB,  PC  HPV  QV  (n=117)  vs.  Placebo
(n=59)
F  (9--23  yrs)  Local  pain,  erythema,
edema  and  fever
Li et  al.  [44]
(2011/3)
RCT,  DB,  PC  HPV  QV  (n=302)  vs.  Placebo
(n=298)
M  (9--15  yrs)  and
F  (9--45  yrs)
Local  pain,  edema  and
pruritus
RCT, randomized controlled trial; DB, double-blind; PB, partially blind; PC, placebo-controlled; MULTI, multicenter; HPV, human papil-
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The  meta-analysis  of  the  ‘‘erythema’’  outcome  included
he  same  articles  used  for  edema.  Of  all  patients  vacci-
ated  for  HPV,  1200  developed  erythema  at  the  injection
ite,  while  802  had  erythema  in  the  placebo  group,  with  an
D=5%  (95%CI:  4--7%,  p<0.001,  I2=88%).
In  turn,  the  meta-analysis  of  the  ‘‘fever’’  outcome
nvolved  four  articles.  Of  the  5900  vaccinated  patients,  609
eveloped  fever,  while  468  of  the  5265  in  the  placebo  group
D
C
rnt; QV, quadrivalent; yrs., years.
ad  the  same  outcome.  The  RD=2%  (95%CI  1--3%,  I2=64%)  was
igniﬁcant  (p<0.003).iscussion
onsidering  that  the  Ministry  of  Health  of  Brazil  has  only
ecently  incorporated  this  vaccine  into  the  immunization
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Figure  2  Meta-analysis  of  outcomes  ‘‘pain’’,  ‘‘edema’’,  ‘‘erythema’’  and  ‘‘fever’’  from  the  results  provided  by  the  selected
RCTs. *M-H,  Mantel-Haenszel;  CI,  conﬁdence  interval;  in  the  forest  plots,  the  horizontal  axis  represents  the  CI  of  risk  difference.
The points  represent  the  risk  difference  in  each  study.  The  dots  located  to  the  right  of  the  median  line  indicate  higher  incidence  of
the outcome  in  the  group  that  received  the  vaccine;  the  size  of  the  dots  represents  the  relative  weight  of  each  study  in  the  ﬁnal
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vertical axis  =  sample  size)  illustrate  the  heterogeneity  between
schedule  of  female  adolescents,  and  also  the  future  pos-
sibility  of  expanding  its  target  audience,  the  study  of
the  safety  proﬁle  of  the  human  papillomavirus  quadriva-
lent  (types  6,  11,  16,  18)  recombinant  vaccine  is  crucial.
Moreover,  considering  its  good  efﬁcacy  demonstrated  in
several  studies,32,33,39,41 the  clear  association  between  cer-
vical  cancer  and  chronic  HPV  infection  and  the  need  for
the  administration  of  more  than  one  dose  to  meet  the
purpose,  the  knowledge  of  possible  adverse  reactions  is
important  to  ensure  adherence  to  the  proposed  vacci-
nation  schedule  and,  consequently,  the  success  of  this
strategy  to  prevent  this  infectious  disease  as  well  as  cervical
cancer.
In  this  context,  the  clinical  trials  selected  for  this  study
suggest  the  existence  of  several  local  and  systemic  adverse
effects,  severe  or  not,  chronic  disease  onset  during  the
study  period  and  new  relevant  medical  conditions  reported
by  the  affected  patients.  However,  most  of  these  clinical
a
t
i
elysis;  **  funnel  plots  (horizontal  axis  =  magnitude  of  the  effect;
ies.
henomena  cannot  be  deﬁned  as  adverse  effects  associated
ith  the  administration  of  the  human  papillomavirus
uadrivalent  (types  6,  11,  16,  18)  recombinant  vaccine,  for
heir  occurrence  has  not  been  compared  to  control  groups,
nd  the  causal  association  has  not  been  established.
In  two  articles,  different  immunization  schedules  were
ested  and  compared  and  no  signiﬁcant  differences  were
ound  regarding  the  occurrence  of  pain  or  other  adverse
ffects  between  the  groups.40,42 The  remaining  12  arti-
les  compared  groups  receiving  the  human  papillomavirus
uadrivalent  (types  6,  11,  16,  18)  recombinant  vaccine  and
ontrol  groups.  For  these  12  studies,  local  adverse  effects
re  noteworthy,  as  they  were  the  most  frequently  associated
ith  HPV  vaccination,  when  compared  to  control  groups.  In
ll  of  these  articles,  there  is  at  least  one  adverse  effect  sta-
istically  associated  with  the  vaccination,  which  shows  the
mportance  of  safety  analysis.  Among  the  effects  were  pain,
rythema,  edema  and  pruritus.
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Pain  was  identiﬁed  in  11  of  the  12  articles  and  this  was  the
ost  common  adverse  effect,  always  associated  with  human
apillomavirus  quadrivalent  (types  6,  11,  16,  18)  recombi-
ant  vaccine  when  compared  to  the  placebo  group,32--36,43,44
o  the  control  group  with  hepatitis  A  vaccine 23,37,39 or  hep-
titis  B  vaccine.38 Edema  was  present  in  ten  articles.  Of
hese,  eight  identiﬁed  edema  as  an  effect  that  was  directly
elated  to  HPV  vaccination.  Erythema  was  described  in  nine
rticles,  but  only  six  showed  a  direct  association  with  vacci-
ation.  Pruritus  was  an  adverse  effect  that  was  rarely  found
mong  the  assessed  articles,  being  present  in  only  three  of
hem.
Given  the  magnitude  of  the  identiﬁed  local  adverse
ffects,  the  performance  of  the  meta-analysis  aimed  not
nly  to  conﬁrm,  but  also  to  quantify  them,  using  statistical
ethods  that  allow  a  joint  assessment  of  trials  investigating
he  association  of  adverse  effects  with  the  human  papil-
omavirus  quadrivalent  (types  6,  11,  16,  18)  recombinant
accine.  The  meta-analyses  performed  in  this  study  showed
 higher  probability  of  vaccinated  individuals  to  develop
ocal  effects,  with  signiﬁcant  difference  of  risk,  especially
egarding  local  pain,  and  to  a  lesser  extent,  erythema  and
dema.
Moreira  et  al.34 suggest  that  the  adjuvant  AS04  may  be
mplicated  in  a  higher  incidence  of  local  adverse  effects;
owever,  its  role  is  of  utmost  importance  to  enhance  the  vac-
ine  immunogenicity.  As  this  ﬁnding  was  exclusively  found
n  the  trial  carried  out  by  these  authors,  further  studies  are
equired  to  determine  the  causal  association,  which  is  likely
o  change  the  use  of  this  adjuvant  in  the  vaccine  manufac-
uring  process.
Among  the  wide  variety  of  systemic  adverse  effects
dentiﬁed  in  this  review,  few  were  actually  related  to  immu-
ization,  such  as  fever  and  myalgia.  Ten  of  the  12  articles
isted  fever  as  an  adverse  effect,  but  only  two  of  them
ere  related  to  vaccination  when  compared  to  controls.  The
isk  of  fever  after  the  administration  of  the  human  papil-
omavirus  quadrivalent  (types  6,  11,  16,  18)  recombinant
accine  observed  in  the  meta-analysis  was  greater  than  that
n  the  placebo  group.  This  fact  should  be  a  warning  to  health
are  professionals  who  recommend  care  after  prescribing
he  vaccine  to  their  patients.  However,  it  is  noteworthy  that
lthough  this  risk  difference  is  signiﬁcant,  it  is  not  sufﬁcient
o  contraindicate  its  use,  based  on  the  beneﬁt  of  protection
gainst  viral  infection  and  cervical  cancer.
Other  mentioned  systemic  effects,  such  as  headache,
ash,  myalgia,  hives,  syncope,  fatigue,39 and  allergies33 were
ystemic  adverse  effects  also  related  to  vaccination,  but
ere  not  included  in  the  meta-analyses,  as  they  were  not
eproduced  in  other  studies.  The  other  systemic  adverse
ffects,  which  differed  between  articles,  were  unrelated  to
he  vaccination  and  showed  no  difference  between  the  study
roups  regarding  their  occurrence,  positively  contributing  to
ts  safety  proﬁle.  Some  of  them  did  not  have  an  explicitly
eported  frequency  of  occurrence,  making  it  difﬁcult  to  ana-
yze  them.  This  observation  leads  us  to  consider  the  need  for
dditional  long-term  studies,  and  with  larger  sample  sizes,
o  that  rare  outcomes  can  be  assessed.32,39Although  they  are  frequent,  more  severe  adverse  effects
elated  to  vaccination  were  not  described  and,  for  the  most
art,  they  were  not  a  cause  of  losses  in  the  completion  of
he  multiple  vaccination  schedule.  It  was  also  observed  that
t
c
oCoelho  PLS  et  al.
he  incidence  of  adverse  effects  is  higher  after  the  ﬁrst  dose
f  the  schedule,  with  decreasing  occurrence  in  subsequent
oses.23,34--36,43
Considering  the  prevalence  of  HPV  infection  in  adoles-
ence  and  the  incidence  and  morbimortality  of  cervical
ancer,  the  risk/beneﬁt  ratio  of  the  vaccine  shows  to  be
ompletely  acceptable,  conﬁrming  its  good  tolerability  and
afety  proposed  by  other  authors,23,32--36,39--44 which  con-
ributes  to  the  effectiveness  of  public  health  policies.
Despite  the  identiﬁcation  of  effects  in  observational
tudies,  which  can  contribute  to  the  construction  of  knowl-
dge,  the  present  study  chose  the  exclusive  selection  of
CTs  with  comparison  to  a  control  group,  especially  those
sing  placebo,  as  studies  with  this  design  allow  establishing
 clear  association  of  adverse  effects  with  vaccination  and
ule  out  the  undesirable  effect  of  confounding  factors,  often
resent  in  observational  designs.  Thus,  the  ﬁndings  here  are
he  result  of  the  knowledge  generated  by  the  maximum  level
f  scientiﬁc  evidence  available  in  the  literature.  However,
t  is  noteworthy  that  the  RCTs  that  evaluate  the  safety  and
eactogenicity  of  the  vaccine  include  a  limited  number  of
ubjects  when  compared  with  the  general  population  of  indi-
iduals  eligible  for  vaccination.  This  characteristic  restricts
he  identiﬁcation  of  rare  or  unknown  adverse  effects.  There-
ore,  the  results  shown  herein  should  be  interpreted  with
aution.
This  study  did  not  differentiate  between  genders,
ecause  although  the  mass  vaccination  was  recommended
or  female  adolescents,  the  male  population  is  also  suscep-
ible  to  infection  and  diseases  caused  by  HPV.  Additionally,
he  male  population  can  play  a key  role  in  disease  transmis-
ion,  and  one  should  consider  the  possibility  of  this  being
 possible  target  of  vaccination  campaigns  in  the  future.
eisinger  et  al.36 suggest  that  the  female  population  reports
ore  adverse  effects  than  the  male  population,  but  no  for-
al  comparison  was  made  between  genders  for  this  ﬁnding.
oreover,  the  selected  articles  showed  great  variability  in
he  assessed  age  group,  including  schoolchildren,  adoles-
ents,  young  adults  and  adults.
This  fact  also  contributed  to  differences  between  the
tudy  populations  and,  possibly,  to  the  external  validity  of
he  obtained  results.  Therefore,  the  selection  of  articles
ould  not  limit  the  age  group,  as  there  was  no  standard
ethodology  between  studies  regarding  the  age  of  the  study
opulation.
The  meta-analyses  showed  moderate  and  high  hetero-
eneity  values  (I2 >  50%),  which  reduces  the  degree  of
onﬁdence  in  the  results  shown  here.  Overall,  the  results
ollowed  the  trend  of  a  large  sample  population  study.32
ome  variables  may  be  attributed  as  the  cause  of  the  hetero-
eneity,  especially  age,  gender  and  sample  size,  suggesting
hat  the  outcomes  studied  in  the  meta-analyses  cannot  be
ependent  on  the  vaccine  only,  but  also  on  the  abovemen-
ioned  factors.  On  the  other  hand,  the  conﬁdence  intervals
f  the  calculated  risk  differences  were  narrow,  due  to  the
imilarity  of  the  results  identiﬁed  in  each  trial  selected  to
omprise  the  meta-analyses,  reinforcing  the  plausibility  of
he  observed  magnitude  effect.Another  methodological  divergence  occurred  regarding
he  control  groups  of  each  study.  Some  studies  performed
omparisons  with  a control  group  that  used  placebo32--36,43,44
r  control  with  hepatitis  A23,37,39 or  hepatitis  B  vaccine.38
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These  articles  were  maintained  in  this  study,  because  hep-
atitis  A  and  B  vaccines  have  a  well-established  use,  with
a  well-deﬁned  safety  proﬁle,  and  can  be  a  good  reference.
However,  the  meta-analysis  used  only  articles  that  compared
the  human  papillomavirus  quadrivalent  (types  6,  11,  16,  18)
recombinant  vaccine  with  placebo,  so  that  the  sample  would
be  as  homogeneous  as  possible.  Moreover,  information  on
the  intensity  of  the  assessed  adverse  effects  has  not  been
demonstrated  in  all  the  selected  studies,  which  might  impair
the  evaluation  of  the  effect  severity.  Our  study,  therefore,
did  not  consider  differences  in  severity  when  all  outcomes
were  analyzed  together.
Although  it  was  not  the  focus  of  this  study,  it  is  notewor-
thy  that,  when  the  bivalent  and  quadrivalent  vaccines  are
compared,  the  results  suggest  that  both  have  similar  safety
proﬁle  and  adverse  effects,  with  a  predominance  of  local
effects.  However,  this  ﬁnding  can  only  be  established  by  per-
forming  further  studies,  of  which  objective  is  to  compare  the
occurrence  of  adverse  effects  between  the  vaccines.
In  this  context,  the  results  shown  here  suggest  that  the
use  of  human  papillomavirus  quadrivalent  (types  6,  11,  16,
18)  recombinant  vaccine  is  potentially  safe  and  well  tol-
erated.  The  main  adverse  effects  related  to  vaccination
are  local  effects,  such  as  pain,  erythema  and  edema.  As
for  systemic  effects,  fever  was  associated  with  vaccina-
tion.  Both  groups  of  adverse  effects  were  not  considered
severe.  Finally,  it  is  concluded  that  the  high  immunogenicity
and  safety  proﬁle  of  the  human  papillomavirus  quadrivalent
(types  6,  11,  16,  18)  recombinant  vaccine  determine  that  its
use  has  an  advantageous  risk/beneﬁt  ratio  and  is  a  favorable
strategy  to  prevent  this  viral  infection  as  well  as  cervical
cancer,  which  supports  the  persistent  encouragement  from
health  professionals  to  provide  HPV  vaccination  to  the  risk
population.
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